The Global Health Body Sounds Alert Over Acute Lack of Obesity Medications

Less than a tenth of individuals eligible to benefit from obesity jabs including Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the drugs.

Given over a billion individuals worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.

According to estimates, over two billion are projected to be obese by 2030 if no action is taken.

"The new guidelines recognises that obesity is a lifelong illness that can be addressed with comprehensive and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the treatments that can assist patients in reducing considerable weight, notes the agency.

Weight-Loss Drug Supply Crisis

Even in the current most optimistic case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.

The guideline calls on countries and companies to expand availability, via strategies including patent sharing.

The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.

How Weight-Loss Drugs Function

GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and boost satiety so individuals consume fewer calories.

Individuals usually see weight reduction within a few weeks of commencing the once-weekly jabs.

Studies indicates patients may put most of the weight back on after a year of halting the treatment, as their usual food cravings come back.

Being overweight or obese elevates your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.